Publications [#386477] of Jichun Xie

Papers Published

1. Khasraw, M; Hotchkiss, K; Zhang, K; Corcoran, A; Owens, E; Noldner, P; Railton, C; Van Batavia, K; Zhou, Y; Jepson, J; Singh, K; McLendon, R; Batich, K; Patel, A; Ayasoufi, K; Brown, M; Calabrese, E; Xie, J; Conejo-Garcia, J; Shaz, B; Hickey, J, A Spatial Multi-Omic Framework Identifies Gliomas Permissive to TIL Expansion., Res Sq (April, 2025) [doi]
   (last updated on 2026/01/16)

   Abstract:
   Tumor-infiltrating lymphocyte (TIL) therapy, recently approved by the FDA for melanoma, is an emerging modality for cell-based immunotherapy. However, its application in immunologically "cold" tumors such as glioblastoma remains limited due to sparse T cell infiltration, antigenic heterogeneity, and a suppressive tumor microenvironment. To identify genomic and spatial determinants of TIL expandability, we performed integrated, multimodal profiling of high-grade gliomas using spectral flow cytometry, TCR sequencing, single-cell RNA-seq, Xenium in situ transcriptomics, and CODEX spatial proteomics. Comparative analysis of TIL-generating (TIL+) versus non-generating (TIL-) tumors revealed that IL7Rexpression, structured perivascular immune clustering, and tumor-intrinsic metabolic programs such as ACSS3 were associated with successful TIL expansion. In contrast, TIL-tumors were enriched for neuronal lineage signatures, immunosuppressive transcripts including TOX and FERMT1, and tumor-connected macrophages. This study defines spatial and molecular correlates of TIL manufacturing success and establishes a genomics-enabled selection platform for adoptive T cell therapy. The profiling approach is now being prospectively implemented in the GIANT clinical trial (NCT06816927), supporting its translational relevance and scalability across glioblastoma and other immune-excluded cancers.